{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:59:25Z","timestamp":1780466365697,"version":"3.54.1"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,6,22]],"date-time":"2014-06-22T00:00:00Z","timestamp":1403395200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s11864-014-0295-3","type":"journal-article","created":{"date-parts":[[2014,6,21]],"date-time":"2014-06-21T06:05:36Z","timestamp":1403330736000},"page":"493-506","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["GIST Treatment Options after Tyrosine Kinase Inhibitors"],"prefix":"10.1007","volume":"15","author":[{"given":"Natthapol","family":"Songdej","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"von Mehren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,22]]},"reference":[{"issue":"22","key":"295_CR1","first-page":"8118","volume":"61","author":"BP Rubin","year":"2001","unstructured":"Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001;61(22):8118\u201321.","journal-title":"Cancer Res"},{"issue":"5607","key":"295_CR2","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1126\/science.1079666","volume":"299","author":"MC Heinrich","year":"2003","unstructured":"Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299(5607):708\u201310.","journal-title":"Science"},{"issue":"23","key":"295_CR3","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1200\/JCO.2005.14.068","volume":"23","author":"CL Corless","year":"2005","unstructured":"Corless CL. PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib. J Clin Oncol. 2005;23(23):5357\u201364.","journal-title":"J Clin Oncol"},{"issue":"6","key":"295_CR4","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1158\/1078-0432.CCR-11-2230","volume":"18","author":"C Miranda","year":"2012","unstructured":"Miranda C, Nucifora M, Molinari F, et al. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res. 2012;18(6):1769\u201376.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"295_CR5","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1073\/pnas.1009199108","volume":"108","author":"KA Janeway","year":"2011","unstructured":"Janeway KA, Kim SY, Lodish M, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A. 2011;108(1):314\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"295_CR6","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1158\/2159-8290.CD-13-0092","volume":"3","author":"JK Killian","year":"2013","unstructured":"Killian JK, Kim SY, Miettinen M, et al. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov. 2013;3(6):648\u201357.","journal-title":"Cancer Discov"},{"issue":"9291","key":"295_CR7","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/S0140-6736(01)06535-7","volume":"358","author":"AT Oosterom van","year":"2001","unstructured":"van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001;358(9291):1421\u20133.","journal-title":"Lancet"},{"issue":"4","key":"295_CR8","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1200\/JCO.2007.13.4403","volume":"26","author":"CD Blanke","year":"2008","unstructured":"Blanke CD, Demetri GD, von Mehren M, et al. Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT. J Clin Oncol. 2008;26(4):620\u20135.","journal-title":"J Clin Oncol"},{"issue":"9669","key":"295_CR9","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(09)60500-6","volume":"373","author":"RP DeMatteo","year":"2009","unstructured":"DeMatteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9669):1097\u2013104.","journal-title":"Lancet"},{"issue":"12","key":"295_CR10","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jama.2012.347","volume":"307","author":"H Joensuu","year":"2012","unstructured":"Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307(12):1265\u201372.","journal-title":"JAMA"},{"issue":"7","key":"295_CR11","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors. N Engl J Med. 2002;347(7):472\u201380.","journal-title":"N Engl J Med"},{"issue":"9440","key":"295_CR12","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","volume":"364","author":"J Verweij","year":"2004","unstructured":"Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364(9440):1127\u201334.","journal-title":"Lancet"},{"issue":"4","key":"295_CR13","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","volume":"26","author":"CD Blanke","year":"2008","unstructured":"Blanke CD, Rankin C, Demetri GD, et al. Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033. J Clin Oncol. 2008;26(4):626\u201332.","journal-title":"J Clin Oncol"},{"issue":"11","key":"295_CR14","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1158\/1078-0432.CCR-04-2245","volume":"11","author":"CR Antonescu","year":"2005","unstructured":"Antonescu CR. Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation. Clin Cancer Res. 2005;11(11):4182\u201390.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"295_CR15","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1158\/1078-0432.CCR-05-1211","volume":"12","author":"E Wardelmann","year":"2006","unstructured":"Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res. 2006;12(6):1743\u20139.","journal-title":"Clin Cancer Res"},{"issue":"29","key":"295_CR16","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1200\/JCO.2006.06.2265","volume":"24","author":"MC Heinrich","year":"2006","unstructured":"Heinrich MC, Corless CL, Blanke CD. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncoly. 2006;24(29):4764\u201374.","journal-title":"J Clin Oncoly"},{"issue":"18 Pt 1","key":"295_CR17","doi-asserted-by":"crossref","first-page":"5398","DOI":"10.1158\/1078-0432.CCR-06-0858","volume":"13","author":"J Desai","year":"2007","unstructured":"Desai J, Shankar S, Heinrich MC, et al. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res. 2007;13(18 Pt 1):5398\u2013405.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"295_CR18","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00432-009-0753-7","volume":"136","author":"C-M Wang","year":"2010","unstructured":"Wang C-M, Huang K, Zhou Y, et al. Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors. J Cancer Res Clin Oncol. 2010;136(7):1065\u201371.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"24","key":"295_CR19","doi-asserted-by":"crossref","first-page":"8387","DOI":"10.1073\/pnas.0803383105","volume":"105","author":"C Tarn","year":"2008","unstructured":"Tarn C, Rink L, Merkel E, et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A. 2008;105(24):8387\u201392.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"295_CR20","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11912-013-0316-6","volume":"15","author":"S Patel","year":"2013","unstructured":"Patel S. Exploring novel therapeutic targets in GIST: focus on the PI3K\/Akt\/mTOR pathway. Curr Oncol Rep. 2013;15(4):386\u201395.","journal-title":"Curr Oncol Rep"},{"issue":"12","key":"295_CR21","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nrc3143","volume":"11","author":"CL Corless","year":"2011","unstructured":"Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11(12):865\u201378.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"295_CR22","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1200\/JCO.2009.24.2099","volume":"28","author":"Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST)","year":"2010","unstructured":"Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol. 2010;28(7):1247\u201353.","journal-title":"J Clin Oncol"},{"issue":"9544","key":"295_CR23","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329\u201338.","journal-title":"Lancet"},{"issue":"9863","key":"295_CR24","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","volume":"381","author":"GD Demetri","year":"2013","unstructured":"Demetri GD, Reichardt P, Kang Y-K, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295\u2013302.","journal-title":"Lancet"},{"issue":"33","key":"295_CR25","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","volume":"26","author":"MC Heinrich","year":"2008","unstructured":"Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26(33):5352\u20139.","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"295_CR26","first-page":"10564","volume":"27","author":"P Reichardt","year":"2009","unstructured":"Reichardt P, Montemurro M, Gelderblom H. Sorafenib fourth-line treatment in imatinib-, sunitinib-, and nilotinib-resistant metastatic GIST: A retrospective analysis. J Clin Oncol (ASCO Meeting Abstracts). 2009;27 Suppl 15:10564.","journal-title":"J Clin Oncol (ASCO Meeting Abstracts)"},{"key":"295_CR27","doi-asserted-by":"crossref","unstructured":"Kindler HL, Campbell NP, Wroblewski K. Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium Trial. Journal of Clinical Oncology (ASCO Meeting Abstracts) 2011;29(Suppl 15):10009.","DOI":"10.1200\/jco.2011.29.15_suppl.10009"},{"issue":"Suppl 15","key":"295_CR28","first-page":"10500","volume":"27","author":"MC Heinrich","year":"2009","unstructured":"Heinrich MC, Carden R, Griffith D. In vitro activity of sorafenib against imatinib-and sunitinib-resistant kinase mutations associated with drug-resistant GI stromal tumors. J Clin Oncol (ASCO Meeting Abstracts). 2009;27 Suppl 15:10500.","journal-title":"J Clin Oncol (ASCO Meeting Abstracts)"},{"key":"295_CR29","doi-asserted-by":"crossref","unstructured":"Reichardt P, Blay J, Gelderblom H. Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): First results from ENEST g3. J Clin Oncol (ASCO Meeting Abstracts). 2010;28 Suppl 15.","DOI":"10.1200\/jco.2010.28.15_suppl.10017"},{"issue":"11","key":"295_CR30","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/bjc.2011.151","volume":"104","author":"H Joensuu","year":"2011","unstructured":"Joensuu H, De Braud F, Grignagni G, et al. Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. Br J Cancer. 2011;104(11):1686\u201390.","journal-title":"Br J Cancer"},{"issue":"9","key":"295_CR31","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1038\/bjc.2013.594","volume":"109","author":"YK Kang","year":"2013","unstructured":"Kang YK, Yoo C, Ryoo BY, Lee JJ, Tan E, Park I. Phase II study of dovitinib in patients with metastatic and\/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib. Br J of Cancer. 2013;109(9):2309\u201315.","journal-title":"Br J of Cancer"},{"issue":"Suppl","key":"295_CR32","first-page":"10006","volume":"29","author":"JC Trent","year":"2011","unstructured":"Trent JC, Wathen K, Mehrenvon M. A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol (ASCO Meeting Abstracts). 2011;29(Suppl):10006.","journal-title":"J Clin Oncol (ASCO Meeting Abstracts)"},{"key":"295_CR33","doi-asserted-by":"crossref","unstructured":"Gardner K, Judson I, Leahy M, Barquin E. Gardner: 9404 A Phase II study of cediranib in patients with metastatic gastrointestinal stromal tumours (GIST) and metastatic soft tissue sarcoma (STS) (including alveolar soft part sarcoma [ASPS]). Eur J Cancer Suppl. 2009;7(2):591\u20131.","DOI":"10.1016\/S1359-6349(09)71992-5"},{"issue":"Suppl 4","key":"295_CR34","first-page":"85","volume":"29","author":"J Blay","year":"2011","unstructured":"Blay J, Le Cesne A, Bin-Bui N, Bouch\u00e9 O, Adenis A. Overall survival benefit with masitinib mesylate in imatinib-naive, locally advanced, or metastatic gastrointestinal stromal tumor (GIST): 4-years follow-up of the French Sarcoma Group phase II trial. J Clin Oncol (ASCO Meeting Abstracts). 2011;29 Suppl 4:85.","journal-title":"J Clin Oncol (ASCO Meeting Abstracts)"},{"issue":"8","key":"295_CR35","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.ejca.2010.02.014","volume":"46","author":"A Cesne Le","year":"2010","unstructured":"Le Cesne A, Blay J-Y, Bui BN, et al. Phase II study of oral masitinib mesilate in imatinib-na\u00efve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur J Cancer. 2010;46(8):1344\u201351.","journal-title":"Eur J Cancer"},{"issue":"16","key":"295_CR36","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1158\/1078-0432.CCR-12-0625","volume":"18","author":"MC Heinrich","year":"2012","unstructured":"Heinrich MC, Griffith D, McKinley A, et al. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res. 2012;18(16):4375\u201384. This paper reports on preclinical data testing crenolanib, a PDGFRA inhibitor, which is the first agent to demonstrate significant inhibition of the PDGFRA D842V mutation.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"295_CR37","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/path.2382","volume":"216","author":"B Liegl","year":"2008","unstructured":"Liegl B, Kepten I, Le C, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol. 2008;216(1):64\u201374.","journal-title":"J Pathol"},{"issue":"1","key":"295_CR38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/PDM.0b013e3181eb931b","volume":"20","author":"Z S\u00e1pi","year":"2011","unstructured":"S\u00e1pi Z, F\u00fcle T, Hajdu M, et al. The activated targets of mTOR signaling pathway are characteristic for PDGFRA mutant and wild-type rather than KIT mutant GISTs. Diagn Mol Pathol. 2011;20(1):22\u201333.","journal-title":"Diagn Mol Pathol"},{"issue":"9","key":"295_CR39","first-page":"3019","volume":"31","author":"MJ R\u00edos-Moreno","year":"2011","unstructured":"R\u00edos-Moreno MJ, Jaramillo S, D\u00edaz-Delgado M, et al. Differential activation of MAPK and PI3K\/AKT\/mTOR pathways and IGF1R expression in gastrointestinal stromal tumors. Anticancer Res. 2011;31(9):3019\u201325.","journal-title":"Anticancer Res"},{"issue":"10","key":"295_CR40","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1093\/annonc\/mdq076","volume":"21","author":"P Sch\u00f6ffski","year":"2010","unstructured":"Sch\u00f6ffski P, Reichardt P, Blay J-Y, et al. A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann Oncol. 2010;21(10):1990\u20138.","journal-title":"Ann Oncol"},{"issue":"Suppl 15","key":"295_CR41","first-page":"10048","volume":"28","author":"P Hohenberger","year":"2010","unstructured":"Hohenberger P, Bauer S, Gruenwald V. Multicenter, single-arm, two-stage phase II trial of everolimus (RAD001) with imatinib in imatinib-resistant patients (pts) with advanced GIST. J Clin (ASCO Meeting Abstracts). 2010;28 Suppl 15:10048.","journal-title":"J Clin (ASCO Meeting Abstracts)"},{"issue":"Suppl 15","key":"295_CR42","first-page":"10038","volume":"28","author":"S Richter","year":"2010","unstructured":"Richter S, Pink D, Hohenberger P. Multicenter, triple-arm, single-stage, phase II trial to determine the efficacy and safety of everolimus (RAD001) in patients with refractory bone or soft tissue sarcomas. J Clin Oncol (ASCO Meeting Abstracts). 2010;28 Suppl 15:10038.","journal-title":"J Clin Oncol (ASCO Meeting Abstracts)"},{"issue":"Suppl 15","key":"295_CR43","first-page":"21515","volume":"28","author":"E Palassini","year":"2008","unstructured":"Palassini E, Fumagalli E, Coco P. Combination of PKC412 and sirolimus in a metastatic patient with PDGFRA-D842V gastrointestinal stromal tumor (GIST). J Clin Oncol (ASCO Meeting Abstracts). 2008;28 Suppl 15:21515.","journal-title":"J Clin Oncol (ASCO Meeting Abstracts)"},{"issue":"Suppl 15","key":"295_CR44","first-page":"10565","volume":"27","author":"C Piovesan","year":"2009","unstructured":"Piovesan C, Fumagalli E, Coco P. Response to sirolimus in combination to tirosine kinase inhibitors (TKI) in three cases of PDGFRA-D842V metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol (ASCO Meeting Abstracts). 2009;27 Suppl 15:10565.","journal-title":"J Clin Oncol (ASCO Meeting Abstracts)"},{"issue":"54","key":"295_CR45","doi-asserted-by":"crossref","first-page":"7560","DOI":"10.1038\/sj.onc.1210558","volume":"26","author":"S Bauer","year":"2007","unstructured":"Bauer S, Duensing A, Demetri GD, Fletcher JA. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase\/AKT is a crucial survival pathway. Oncogene. 2007;26(54):7560\u20138.","journal-title":"Oncogene"},{"key":"295_CR46","doi-asserted-by":"crossref","unstructured":"Li F, Growney J, Battalagine L. The effect combining the KIT inhibitor Imatinib with the PI3K inhibitor BKM120 or the dual PI3K\/mTOR inhibitor BEZ235 on the proliferation of gastrointestinal stromal tumor cell lines. 102nd Annual Meeting of the AACR Chicago 2012; Abstract 2239.","DOI":"10.1158\/1538-7445.AM2012-2239"},{"issue":"Suppl 15","key":"295_CR47","first-page":"10020","volume":"28","author":"G Floris","year":"2010","unstructured":"Floris G, Sciot R, Wozniak A. Activity of GDC-0941, an inhibitor of phosphoinositol 3 kinase (PI3K), in gastrointestinal stromal tumor (GIST) xenograft and duration of response after discontinuation of treatment in combination with imatinib. J Clin Onco (ASCO Meeting Abstracts). 2010;28 Suppl 15:10020.","journal-title":"J Clin Onco (ASCO Meeting Abstracts)"},{"issue":"Suppl)","key":"295_CR48","first-page":"10030","volume":"30","author":"T Looy Van","year":"2012","unstructured":"Van Looy T, Wozniak A, Sciot R. Efficacy of a phosphoinositol 3 kinase (PI3K) inhibitor in gastrointestinal stromal tumor (GIST) models. J Clin Oncol (ASCO Meeting Abstracts). 2012;30(Suppl)):10030.","journal-title":"J Clin Oncol (ASCO Meeting Abstracts)"},{"issue":"Suppl 15","key":"295_CR49","first-page":"2558","volume":"27","author":"EG Chiorean","year":"2009","unstructured":"Chiorean EG, Mahadevan D. Phase I evaluation of SF1126, a vascular targeted PI3K inhibitor, administered twice weekly IV in patients with refractory solid tumors. J Clin Oncol (ASCO Meeting Abstracts). 2009;27 Suppl 15:2558.","journal-title":"J Clin Oncol (ASCO Meeting Abstracts)"},{"issue":"Suppl","key":"295_CR50","first-page":"3020","volume":"29","author":"AJ Wagner","year":"2011","unstructured":"Wagner AJ, Bendell JC, Dolly S. A first-in-human phase I study to evaluate GDC-0980, an oral PI3K\/mTOR inhibitor, administered QD in patients with advanced solid tumors. J Clin Oncol (ASCO Meeting Abstracts). 2011;29(Suppl):3020.","journal-title":"J Clin Oncol (ASCO Meeting Abstracts)"},{"issue":"Suppl 15","key":"295_CR51","first-page":"10563","volume":"27","author":"AP Conley","year":"2009","unstructured":"Conley AP, Araujo D, Ludwig J, Ravi V. A randomized phase II study of perifosine (P) plus imatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol (ASCO Meeting Abstracts). 2009;27 Suppl 15:10563.","journal-title":"J Clin Oncol (ASCO Meeting Abstracts)"},{"issue":"3","key":"295_CR52","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2011.36.1360","volume":"30","author":"JC Bendell","year":"2012","unstructured":"Bendell JC, Rodon J, Burris HA. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2012;30(3):282\u201390.","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"295_CR53","first-page":"2531","volume":"31","author":"A Gonzalez-Angulo","year":"2013","unstructured":"Gonzalez-Angulo A, Juric D, Argiles G. Safety, pharmcokinetics, and preliminary activity of the \u03b1-specific PI3K inhibitor BYL719: Results from the first in-human study. J Clin Oncol (ASCO Meeting Abstracts). 2013;31(Suppl):2531.","journal-title":"J Clin Oncol (ASCO Meeting Abstracts)"},{"issue":"10","key":"295_CR54","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc1716","volume":"5","author":"L Whitesell","year":"2005","unstructured":"Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005;5(10):761\u20132.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"295_CR55","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2887","volume":"10","author":"J Trepel","year":"2010","unstructured":"Trepel J, Mollapour M, Giaccone G. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010;10(8):537\u201349.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"295_CR56","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2003-07-2477","volume":"103","author":"G Fumo","year":"2004","unstructured":"Fumo G, Akin C, Metcalfe DD, Neckers L. 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood. 2004;103(3):1078\u201384.","journal-title":"Blood"},{"issue":"18","key":"295_CR57","doi-asserted-by":"crossref","first-page":"9153","DOI":"10.1158\/0008-5472.CAN-06-0165","volume":"66","author":"S Bauer","year":"2006","unstructured":"Bauer S, Yu LK, Demetri GD, Fletcher JA. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res. 2006;66(18):9153\u201361.","journal-title":"Cancer Res"},{"key":"295_CR58","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1158\/1535-7163.MCT-08-0758","volume":"8","author":"K Lundgren","year":"2009","unstructured":"Lundgren K, Zhang H, Brekken J, Huser N. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther. 2009;8:921\u20139.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"295_CR59","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1158\/1078-0432.CCR-06-1863","volume":"13","author":"DB Solit","year":"2007","unstructured":"Solit DB, Ivy SP, Kopil C, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res. 2007;13(6):1775\u201382.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"295_CR60","doi-asserted-by":"crossref","first-page":"B184","DOI":"10.1158\/1535-7163.TARG-09-B184","volume":"8","author":"JA Fletcher","year":"2009","unstructured":"Fletcher JA, Debiec-Rychter M, Swank S, Morgan J. HSP90 inhibitor STA-9090 potently suppresses secondary KIT kinase-domain mutations responsible for gastrointestinal stromal tumor (GIST) progression during imatinib therapy. Mol Cancer Ther. 2009;8 Suppl 1:B184.","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"295_CR61","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1158\/1535-7163.MCT-11-0148","volume":"10","author":"G Floris","year":"2011","unstructured":"Floris G, Debiec-Rychter M, Wozniak A, et al. The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors. Mol Cancer Ther. 2011;10(10):1897\u2013908.","journal-title":"Mol Cancer Ther"},{"issue":"17","key":"295_CR62","doi-asserted-by":"crossref","first-page":"5604","DOI":"10.1158\/1078-0432.CCR-11-0562","volume":"17","author":"G Floris","year":"2011","unstructured":"Floris G, Sciot R, Wozniak A, et al. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations. Clin Cancer Res. 2011;17(17):5604\u201314.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"295_CR63","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1158\/1535-7163.MCT-11-1046","volume":"11","author":"T Smyth","year":"2012","unstructured":"Smyth T, Van Looy T, Curry JE, et al. The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models. Mol Cancer Ther. 2012;11(8):1799\u2013808.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"295_CR64","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4161\/auto.22802","volume":"9","author":"Y-S Hsueh","year":"2013","unstructured":"Hsueh Y-S, Yen C-C, Shih N-Y, Chiang N-J, Li C-F, Chen L-T. Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors. Autophagy. 2013;9(2):220\u201333.","journal-title":"Autophagy"},{"issue":"Suppl 15","key":"295_CR65","first-page":"10503","volume":"26","author":"AJ Wagner","year":"2008","unstructured":"Wagner AJ, Morgan JA, Chugh R, Rosen LS. Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: Clinical results from phase I trial. J Clin Oncol (ASCO Meeting Abstracts). 2008;26 Suppl 15:10503.","journal-title":"J Clin Oncol (ASCO Meeting Abstracts)"},{"key":"295_CR66","doi-asserted-by":"crossref","unstructured":"Elfiky A, Saif MW, Beeram M, O'Brien S. BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience. J Clin Oncol (ASCO Meeting Abstracts). 2008;26 Suppl 15.","DOI":"10.1200\/jco.2008.26.15_suppl.2503"},{"issue":"Suppl 15","key":"295_CR67","first-page":"2528","volume":"28","author":"TA Samuel","year":"2010","unstructured":"Samuel TA, Sessa C, Britten C, Milligan KS. AUY922, a novel HSP90 inhibitor: final results of a first-in-human study in patients with advanced solid malignancies. J Clin Oncol (ASCO Meeting Abstracts). 2010;28 Suppl 15:2528.","journal-title":"J Clin Oncol (ASCO Meeting Abstracts)"},{"key":"295_CR68","unstructured":"Demetri GD, Le Cesne A, Mehren von M. Final results from a phase III study of IPI-504 (retaspimycin hydrochloride) versus placebo in patients (pts) with gastrointestinal stromal tumors (GIST) following failure of kinase inhibitor therapies. ASCO Gastrointestinal Cancers Symposium 2010; abstract 64."},{"issue":"21","key":"295_CR69","doi-asserted-by":"crossref","first-page":"6020","DOI":"10.1158\/1078-0432.CCR-13-0953","volume":"19","author":"AJ Wagner","year":"2013","unstructured":"Wagner AJ, Chugh R, Rosen LS, et al. A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas. Clin Cancer Res. 2013;19(21):6020\u20139.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"295_CR70","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/annonc\/mds275","volume":"24","author":"MA Dickson","year":"2013","unstructured":"Dickson MA, Okuno SH, Keohan ML, et al. Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. Ann Oncol. 2013;24(1):252\u20137. Clinical trial utilizing a HSP-90 inhibitor demonstrating some stabilization of disease.","journal-title":"Ann Oncol"},{"issue":"Suppl","key":"295_CR71","first-page":"10011","volume":"29","author":"GD Demetri","year":"2011","unstructured":"Demetri GD, Heinrich MC. An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and\/or unresectable GIST. J Clin Oncol (ASCO Meeting Abstracts). 2011;29(Suppl):10011.","journal-title":"J Clin Oncol (ASCO Meeting Abstracts)"},{"issue":"1","key":"295_CR72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1535-7163.MCT-06-0080","volume":"6","author":"D Sachdev","year":"2007","unstructured":"Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther. 2007;6(1):1\u201312.","journal-title":"Mol Cancer Ther"},{"issue":"19","key":"295_CR73","doi-asserted-by":"crossref","first-page":"9084","DOI":"10.1158\/0008-5472.CAN-07-1938","volume":"67","author":"KA Janeway","year":"2007","unstructured":"Janeway KA, Liegl B, Harlow A, et al. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res. 2007;67(19):9084\u20138.","journal-title":"Cancer Res"},{"issue":"Suppl 15","key":"295_CR74","first-page":"10506","volume":"27","author":"CL Corless","year":"2009","unstructured":"Corless CL, Beadling C, Justusson E. Evaluation of the presence of IGF1R overexpression in wild-type and kinase mutant GI stromal tumors. J ClinOncol (ASCO Meeting Abstracts). 2009;27 Suppl 15:10506.","journal-title":"J ClinOncol (ASCO Meeting Abstracts)"},{"issue":"1","key":"295_CR75","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/PAS.0b013e3182613c86","volume":"37","author":"J Lasota","year":"2013","unstructured":"Lasota J, Wang Z, Kim SY, Helman L. Expression of the receptor for type 1 insulin-like growth factor (IGF1R) in gastrointestinal stromal tumors: an immunohistochemical study of 1078 cases with diagnostic and therapeutic implications. Am J Surg Pathol. 2013;37(1):114\u20139. The largest pathology study of expression of IGF1R in GIST.","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"295_CR76","first-page":"214","volume":"52","author":"MG Belinsky","year":"2013","unstructured":"Belinsky MG, Rink L, Flieder DB. Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild type SDHB-negative gastrointestinal stromal tumors. Genes. 2013;52(2):214\u201324. Report of Wild type GIST evaluating IGF1R expression as well as mutations in SDH family members, reporting SDHA mutations which appear to be common in older patients with SDH-deficient GIST.","journal-title":"Genes"},{"issue":"Suppl 1","key":"295_CR77","first-page":"S162","volume":"28","author":"FL Day","year":"2011","unstructured":"Day FL, Desai J, Corless CL, Heinrich MC, Zalcberg J. Neurofibromatosis type 1-associated wild-type gastrointestinal stromal tumor treated with anti-IGF-1R monoclonal antibody. Med Oncol. 2011;28 Suppl 1:S162\u20134.","journal-title":"Med Oncol"},{"issue":"3","key":"295_CR78","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00280-013-2372-x","volume":"73","author":"D Mahadevan","year":"2014","unstructured":"Mahadevan D, Sutton GR, Arteta-Bulos R, et al. Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. Cancer Chemother Pharmacol. 2014;73(3):467\u201373.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"295_CR79","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1172\/JCI21102","volume":"114","author":"C Borg","year":"2004","unstructured":"Borg C, Terme M, Ta\u00efeb J, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest. 2004;114(3):379\u201388.","journal-title":"J Clin Invest"},{"issue":"8","key":"295_CR80","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1158\/0008-5472.CAN-08-3807","volume":"69","author":"C M\u00e9nard","year":"2009","unstructured":"M\u00e9nard C, Blay J-Y, Borg C, et al. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res. 2009;69(8):3563\u20139. A study reporting the predictive value of IFN-gamma and NK cells in GIST; this group was one of the first to report the potential role of NK cells in GIST and in response to imatinib.","journal-title":"Cancer Res"},{"issue":"4","key":"295_CR81","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/MEG.0b013e3282f3a403","volume":"20","author":"S Cameron","year":"2008","unstructured":"Cameron S, Haller F, Dudas J, et al. Immune cells in primary gastrointestinal stromal tumors. Eur J Gastroenterol Hepatol. 2008;20(4):327\u201334.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"295_CR82","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/ijc.25113","volume":"127","author":"M Dongen van","year":"2010","unstructured":"van Dongen M, Savage NDL, Jordanova ES, et al. Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. Int J Cancer. 2010;127(4):899\u2013909.","journal-title":"Int J Cancer"},{"key":"295_CR83","doi-asserted-by":"crossref","unstructured":"Rusakiewicz S, Semeraro M, Sarabi M, et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res. 2013;73(12):3499\u2013510.","DOI":"10.1158\/0008-5472.CAN-13-0371"},{"issue":"9","key":"295_CR84","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/nm.2438","volume":"17","author":"VP Balachandran","year":"2012","unstructured":"Balachandran VP, Cavnar MJ, Zeng S, et al. Imatinib potentiates anti-tumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2012;17(9):1094\u2013100. Preclinical study in a GIST mouse model demonstrating the importance of T cells in the antitumor response of imatinib.","journal-title":"Nat Med"},{"issue":"7","key":"295_CR85","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00262-011-1185-1","volume":"61","author":"LL Chen","year":"2012","unstructured":"Chen LL, Chen X, Choi H, et al. Exploiting antitumor immunity to overcome relapse and improve remission duration. Cancer Immunol Immunother. 2012;61(7):1113\u201324.","journal-title":"Cancer Immunol Immunother"},{"issue":"7154","key":"295_CR86","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/448645a","volume":"448","author":"CR Chong","year":"2007","unstructured":"Chong CR, Sullivan DJ. New uses for old drugs. Nature. 2007;448(7154):645\u20136.","journal-title":"Nature"},{"issue":"4","key":"295_CR87","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1158\/0008-5472.CAN-13-1955","volume":"74","author":"S Boichuk","year":"2014","unstructured":"Boichuk S, Lee DJ, Mehalek KR, et al. Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumors. Cancer Res. 2014;74(4):1200\u201313. One of two papers recently reporting the results of drug repurposing studies.","journal-title":"Cancer Res"},{"issue":"7","key":"295_CR88","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1158\/1535-7163.MCT-12-0968","volume":"12","author":"ZY Pessetto","year":"2013","unstructured":"Pessetto ZY, Weir SJ, Sethi G, Broward MA, Godwin AK. Drug repurposing for gastrointestinal stromal tumor. Mol Cancer Ther. 2013;12(7):1299\u2013309. Second paper reporting the results of drug repurposing studies.","journal-title":"Mol Cancer Ther"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-014-0295-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-014-0295-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-014-0295-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T23:03:10Z","timestamp":1716850990000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-014-0295-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,22]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["295"],"URL":"https:\/\/doi.org\/10.1007\/s11864-014-0295-3","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,22]]}}}